Mutations in mammalian target of rapamycin regulator <i>DEPDC5</i> cause focal epilepsy with brain malformations

Ingrid E. Scheffer(Royal Children's Hospital), Sarah E. Heron(University of South Australia), Brigid M. Regan(The University of Melbourne), Simone Mandelstam(Royal Children's Hospital), Douglas E. Crompton(Northern Health), Bree Hodgson(University of South Australia), Laura Licchetta(University of Bologna), Federica Provini(University of Bologna), Francesca Bisulli(University of Bologna), Lata Vadlamudi(The University of Queensland), Jozef Gécz(The University of Adelaide), Alan Connelly(The University of Melbourne), Paolo Tinuper(University of Bologna), Michael G. Ricos(University of South Australia), Samuel F. Berkovic(The University of Melbourne), Leanne M. Dibbens(University of South Australia)
Annals of Neurology
March 3, 2014
Cited by 222Open Access
Full Text

Abstract

We recently identified DEPDC5 as the gene for familial focal epilepsy with variable foci and found mutations in >10% of small families with nonlesional focal epilepsy. Here we show that DEPDC5 mutations are associated with both lesional and nonlesional epilepsies, even within the same family. DEPDC5-associated malformations include bottom-of-the-sulcus dysplasia (3 members from 2 families), and focal band heterotopia (1 individual). DEPDC5 negatively regulates the mammalian target of rapamycin (mTOR) pathway, which plays a key role in cell growth. The clinicoradiological phenotypes associated with DEPDC5 mutations share features with the archetypal mTORopathy, tuberous sclerosis, raising the possibility of therapies targeted to this pathway.


Related Papers

No related papers found

Powered by citation graph analysis